Primary mFOLFOX6 Plus Bevacizumab Without Resection of the Primary Tumor for Patients Presenting With Surgically Unresectable Metastatic Colon Cancer and an Intact Asymptomatic Colon Cancer: Definitive Analysis of NSABP Trial C-10

Major concerns surround combining chemotherapy with bevacizumab in patients with colon cancer presenting with an asymptomatic intact primary tumor (IPT) and synchronous yet unresectable metastatic disease. Surgical resection of asymptomatic IPT is controversial. Eligibility for this prospective, mul...

Full description

Saved in:
Bibliographic Details
Published in:Journal of clinical oncology Vol. 30; no. 26; pp. 3223 - 3228
Main Authors: MCCAHILL, Laurence E, YOTHERS, Greg, WAGMAN, Lawrence D, O'CONNELL, Michael J, WOLMARK, Norman, SHARIF, Saima, PETRELLI, Nicholas J, LAI, Lily Lau, BECHAR, Naftali, GIGUERE, Jeffrey K, DAKHIL, Shaker R, FEHRENBACHER, Louis, LOPA, Samia H
Format: Journal Article
Language:English
Published: Alexandria, VA American Society of Clinical Oncology 10-09-2012
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first